Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sargramostim Safety and Tolerability With Standard Of Care Ipilimumab Containing Therapy in Patients With Solid Tumors

NCT05284214 is registered in ClinicalTrials.gov with Partner Therapeutics, Inc. as lead sponsor.

NCT NCT05284214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05284214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sargramostim Safety and Tolerability With Standard Of Care Ipilimumab Containing Therapy in Patients With Solid Tumors
Lead sponsor
Partner Therapeutics, Inc.
Phase
Phase 2
Overall status
Withdrawn
Start date
January 31, 2024
Completion date
September 30, 2025
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, solid tumor, adult